Reported Earnings • Jul 18
Full year 2026 earnings released: ₹21.15 loss per share (vs ₹3.86 loss in FY 2025) Full year 2026 results: ₹21.15 loss per share (further deteriorated from ₹3.86 loss in FY 2025). Revenue: ₹763.1m (down 37% from FY 2025). Net loss: ₹1.76b (loss widened 452% from FY 2025). Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Announcement • Jul 15
Vivimed Labs Limited to Report Q4, 2026 Results on Jul 17, 2026 Vivimed Labs Limited announced that they will report Q4, 2026 results at 4:00 PM, Indian Standard Time on Jul 17, 2026 Announcement • May 18
Vivimed Labs Limited to Report Q4, 2026 Results on May 28, 2026 Vivimed Labs Limited announced that they will report Q4, 2026 results at 4:00 PM, Indian Standard Time on May 28, 2026 Reported Earnings • Mar 15
Third quarter 2026 earnings released: ₹2.00 loss per share (vs ₹0.72 loss in 3Q 2025) Third quarter 2026 results: ₹2.00 loss per share (further deteriorated from ₹0.72 loss in 3Q 2025). Revenue: ₹159.9m (down 56% from 3Q 2025). Net loss: ₹165.5m (loss widened 177% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Announcement • Feb 02
Vivimed Labs Limited to Report Q3, 2026 Results on Feb 13, 2026 Vivimed Labs Limited announced that they will report Q3, 2026 results on Feb 13, 2026 Announcement • Oct 28
Vivimed Labs Limited to Report Q2, 2026 Results on Nov 13, 2025 Vivimed Labs Limited announced that they will report Q2, 2026 results on Nov 13, 2025 Announcement • Sep 08
Vivimed Labs Limited, Annual General Meeting, Sep 30, 2025 Vivimed Labs Limited, Annual General Meeting, Sep 30, 2025, at 15:00 Indian Standard Time. Announcement • Aug 02
Vivimed Labs Limited to Report Q1, 2026 Results on Aug 13, 2025 Vivimed Labs Limited announced that they will report Q1, 2026 results on Aug 13, 2025 Announcement • May 13
Vivimed Labs Limited to Report Q4, 2025 Results on May 30, 2025 Vivimed Labs Limited announced that they will report Q4, 2025 results on May 30, 2025 Announcement • Jan 30
Vivimed Labs Limited to Report Q3, 2025 Results on Feb 14, 2025 Vivimed Labs Limited announced that they will report Q3, 2025 results on Feb 14, 2025 Announcement • Jan 04
Vivimed Labs Limited Approves Board Appointments Vivimed Labs Limited announced that at its AGM held on 3 January 2025, the shareholders approved appointment of Ms. Subbarathnamma Palepu and Mr. Jarugula Siva Prasad as an independent directors of the company. Announcement • Aug 23
Vivimed Labs Limited to Report Q4, 2024 Results on Sep 06, 2024 Vivimed Labs Limited announced that they will report Q4, 2024 results at 4:00 PM, Indian Standard Time on Sep 06, 2024 Announcement • May 10
Vivimed Labs Limited to Report Q4, 2024 Results on May 20, 2024 Vivimed Labs Limited announced that they will report Q4, 2024 results on May 20, 2024 Announcement • Feb 01
Vivimed Labs Limited to Report Nine Months, 2024 Results on Feb 14, 2024 Vivimed Labs Limited announced that they will report nine months, 2024 results on Feb 14, 2024 Announcement • Oct 29
Vivimed Labs Limited to Report Q2, 2024 Results on Nov 14, 2023 Vivimed Labs Limited announced that they will report Q2, 2024 results at 4:00 PM, Indian Standard Time on Nov 14, 2023 Announcement • Oct 19
Vivimed Labs Limited, Annual General Meeting, Nov 13, 2023 Vivimed Labs Limited, Annual General Meeting, Nov 13, 2023. Announcement • Jul 29
Vivimed Labs Limited to Report Q1, 2024 Results on Aug 14, 2023 Vivimed Labs Limited announced that they will report Q1, 2024 results at 4:00 PM, Indian Standard Time on Aug 14, 2023 Reported Earnings • Jun 04
Full year 2023 earnings released: ₹39.62 loss per share (vs ₹8.16 loss in FY 2022) Full year 2023 results: ₹39.62 loss per share (further deteriorated from ₹8.16 loss in FY 2022). Revenue: ₹1.88b (down 21% from FY 2022). Net loss: ₹3.29b (loss widened 386% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings. Announcement • May 19
Vivimed Labs Limited to Report Q4, 2023 Results on May 30, 2023 Vivimed Labs Limited announced that they will report Q4, 2023 results on May 30, 2023 Reported Earnings • Feb 14
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: ₹557.9m (flat on 3Q 2022). Net loss: ₹183.1m (loss narrowed 23% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Board Change • Feb 06
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Woman Director Aparna Bidarkar was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Feb 02
Vivimed Labs Limited to Report Q3, 2023 Results on Feb 13, 2023 Vivimed Labs Limited announced that they will report Q3, 2023 results on Feb 13, 2023 Announcement • Jan 14
Vivimed Labs Limited, Annual General Meeting, Feb 17, 2023 Vivimed Labs Limited, Annual General Meeting, Feb 17, 2023, at 12:30 Indian Standard Time. Location: Plot No.78-A, Kolhar Industrial Area Bidar-585403, Karnataka Bidar India Agenda: To consider and adopt (a) the audited standalone financial statement of the Company for the financial year ended 31st March, 2021 and the reports of the Board of Directors and the Auditors thereon; and (b) the audited consolidated financial statement of the Company for the financial year ended 31st March, 2021 and the report of Auditors thereon and in this regard; to appoint Directors; to ratify the remuneration payable to M/s. A.S. Rao & Co, Cost Accountants to audit the cost records for the financial year ending 31st March, 2022; and to consider other matters. Reported Earnings • Nov 19
Second quarter 2023 earnings released: ₹2.66 loss per share (vs ₹2.81 loss in 2Q 2022) Second quarter 2023 results: ₹2.66 loss per share (improved from ₹2.81 loss in 2Q 2022). Revenue: ₹443.7m (down 19% from 2Q 2022). Net loss: ₹220.3m (loss narrowed 5.4% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 10% per year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Additional Non-Executive Independent Woman Director Aparna Bidarkar was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 14
First quarter 2023 earnings released: ₹2.68 loss per share (vs ₹0.28 loss in 1Q 2022) First quarter 2023 results: ₹2.68 loss per share (down from ₹0.28 loss in 1Q 2022). Revenue: ₹501.9m (down 24% from 1Q 2022). Net loss: ₹222.0m (loss widened ₹198.7m from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Reported Earnings • Jun 08
Full year 2022 earnings released: ₹8.16 loss per share (vs ₹9.38 loss in FY 2021) Full year 2022 results: ₹8.16 loss per share (up from ₹9.38 loss in FY 2021). Revenue: ₹2.39b (down 73% from FY 2021). Net loss: ₹676.5m (loss narrowed 13% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Additional Non-Executive Independent Woman Director Aparna Bidarkar was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 17
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: ₹2.86 loss per share (up from ₹5.99 loss in 3Q 2021). Revenue: ₹561.6m (down 80% from 3Q 2021). Net loss: ₹236.8m (loss narrowed 52% from 3Q 2021). Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) were also behind analyst expectations. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance. Reported Earnings • Nov 16
Second quarter 2022 earnings released: ₹2.81 loss per share (vs ₹1.64 loss in 2Q 2021) The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2022 results: Revenue: ₹545.2m (down 76% from 2Q 2021). Net loss: ₹233.0m (loss widened 71% from 2Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 15
First quarter 2022 earnings released: ₹0.28 loss per share (vs ₹1.55 profit in 1Q 2021) The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2022 results: Revenue: ₹661.7m (down 80% from 1Q 2021). Net loss: ₹23.4m (down 118% from profit in 1Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance. Reported Earnings • Jul 02
Full year 2021 earnings released: ₹9.38 loss per share (vs ₹13.16 loss in FY 2020) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: ₹8.71b (down 18% from FY 2020). Net loss: ₹778.0m (loss narrowed 29% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance. Reported Earnings • Feb 17
Third quarter 2021 earnings released: ₹5.99 loss per share (vs ₹3.87 loss in 3Q 2020) The company reported a mediocre third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: ₹2.82b (up 41% from 3Q 2020). Net loss: ₹495.5m (loss widened 55% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Feb 15
New 90-day low: ₹14.65 The company is down 17% from its price of ₹17.55 on 17 November 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period. 
